Vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination: a rare case report

T. Kosaka, S. Nakazawa, T. Ibe, K. Shirabe
{"title":"Vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination: a rare case report","authors":"T. Kosaka, S. Nakazawa, T. Ibe, K. Shirabe","doi":"10.21037/amj-22-13","DOIUrl":null,"url":null,"abstract":"Background: Thymic hyperplasia has occasionally been reported as an immune response to vaccination for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). We herein report a rare case of a vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination. Case Description: A woman in her forties presented with continuous fever after receiving her first mRNA-1273 SARS-CoV-2 vaccination. Chest computed tomography (CT) examination revealed an anterior mediastinal mass of 66-mm in diameter. She was referred to our hospital for evaluation of the anterior mediastinal mass.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed markedly increased uptake in the mediastinal mass. The differential diagnosis included thymoma, thymic cancer, and lymphoma. Although a CT scan performed 25 days after vaccination showed that the mediastinal mass had shrunk to 32 mm, the lesion was still present and a needle biopsy was performed. Unfortunately, accurate pathological examination could not be achieved because of small specimen. A surgical biopsy by the thoracoscopic approach was next planned to rule out malignancy. However, a CT scan prior to surgical biopsy performed 2 months after vaccination revealed that the mediastinal mass had completely disappeared. The surgical biopsy was cancelled. Because there was no residual lesion at 6 months, we concluded that the mediastinal mass was an adverse effect of the SARS-CoV-2 vaccination, presenting as a transient hyperplasia of the thymus. Conclusions: It is important to distinguish an immune response from a malignancy to avoid unnecessary surgery or treatment. Our case warns us that we should take into account the timing of SARS-CoV2 vaccination when we encounter a patient with mediastinal mass. © AME Medical Journal. All rights reserved.","PeriodicalId":72157,"journal":{"name":"AME medical journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AME medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/amj-22-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Thymic hyperplasia has occasionally been reported as an immune response to vaccination for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). We herein report a rare case of a vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination. Case Description: A woman in her forties presented with continuous fever after receiving her first mRNA-1273 SARS-CoV-2 vaccination. Chest computed tomography (CT) examination revealed an anterior mediastinal mass of 66-mm in diameter. She was referred to our hospital for evaluation of the anterior mediastinal mass.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed markedly increased uptake in the mediastinal mass. The differential diagnosis included thymoma, thymic cancer, and lymphoma. Although a CT scan performed 25 days after vaccination showed that the mediastinal mass had shrunk to 32 mm, the lesion was still present and a needle biopsy was performed. Unfortunately, accurate pathological examination could not be achieved because of small specimen. A surgical biopsy by the thoracoscopic approach was next planned to rule out malignancy. However, a CT scan prior to surgical biopsy performed 2 months after vaccination revealed that the mediastinal mass had completely disappeared. The surgical biopsy was cancelled. Because there was no residual lesion at 6 months, we concluded that the mediastinal mass was an adverse effect of the SARS-CoV-2 vaccination, presenting as a transient hyperplasia of the thymus. Conclusions: It is important to distinguish an immune response from a malignancy to avoid unnecessary surgery or treatment. Our case warns us that we should take into account the timing of SARS-CoV2 vaccination when we encounter a patient with mediastinal mass. © AME Medical Journal. All rights reserved.
消失性纵隔肿块与信使核糖核酸严重急性呼吸系统综合征冠状病毒2型疫苗接种相关:一例罕见病例报告
背景:胸腺增生偶尔被报道为对严重急性呼吸综合征冠状病毒2型(严重急性呼吸系统综合征冠状病毒-2型)疫苗接种的免疫反应。我们在此报告了一例罕见的与信使核糖核酸严重急性呼吸系统综合征冠状病毒2型疫苗接种相关的纵隔肿块消失病例。病例描述:一名四十多岁的女性在接受第一次mRNA-1273严重急性呼吸系统综合征冠状病毒2型疫苗接种后出现持续发烧。胸部计算机断层扫描(CT)检查显示前纵隔肿块直径66毫米。她被转诊到我院评估前纵隔肿块。18F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)显示纵隔肿块的摄取明显增加。鉴别诊断包括胸腺瘤、胸腺瘤癌症和淋巴瘤。尽管接种疫苗后25天进行的CT扫描显示纵隔肿块已缩小至32毫米,但病变仍然存在,并进行了针活检。遗憾的是,由于标本太小,无法进行准确的病理检查。下一步计划通过胸腔镜手术活检来排除恶性肿瘤。然而,在接种疫苗2个月后进行的手术活检前的CT扫描显示纵隔肿块已经完全消失。手术活组织检查被取消。由于6个月时没有残留病变,我们得出结论,纵隔肿块是接种严重急性呼吸系统综合征冠状病毒2型疫苗的不良反应,表现为胸腺的短暂增生。结论:区分免疫反应和恶性肿瘤是很重要的,以避免不必要的手术或治疗。我们的病例警告我们,当我们遇到纵隔肿块患者时,应该考虑接种严重急性呼吸系统综合征冠状病毒2型疫苗的时间。©AME医学杂志。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信